Pancreatic Cancer Action Network
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Pancreatic Cancer Action Network sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Pancreatic Cancer Action Network: 3 sponsored US clinical trials, none currently recruiting.
Pancreatic Cancer Action Network sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pancreas Ductal Adenocarcinoma, with 1 trials.
Upper-quartile sponsor footprint
Pancreatic Cancer Action Network sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Early Detection Initiative for Pancreatic Cancer
NCT04662879
A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients
NCT04581343
A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer
NCT04229004
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Therapeutic Areas
How the Pancreatic Cancer Action Network archive is shaped
3 indexed studies, none listed as recruiting (0% open); 2 completed (67%).
Phase mix: 1 late (III/IV) vs 1 early (I/II) (balanced across stages).
Top condition: Pancreas Ductal Adenocarcinoma (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Pancreatic Cancer Action Network: archived-pipeline peers nationwide
Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Pancreatic Cancer Action Network sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 archived trials
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
- 3EO Health · 0% recruiting · 2 trials
Related
What to do with this Pancreatic Cancer Action Network page
3 registered trials is a research-attention snapshot, not an endorsement of Pancreatic Cancer Action Network or any single study.
- None of Pancreatic Cancer Action Network's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Pancreas Ductal Adenocarcinoma is the condition Pancreatic Cancer Action Network studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pancreas Ductal Adenocarcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Pancreatic Cancer Action Network pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.